{"nctId":"NCT01224015","briefTitle":"Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines and Frown Lines","startDateStruct":{"date":"2011-05"},"conditions":["Facial Rhytides","Crow's Feet Lines","Glabellar Lines"],"count":684,"armGroups":[{"label":"onabotulinumtoxinA 24U","type":"OTHER","interventionNames":["Drug: normal saline","Biological: onabotulinumtoxinA 24 U"]},{"label":"placebo (normal saline)","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: normal saline"]},{"label":"onabotulinumtoxinA 44U","type":"EXPERIMENTAL","interventionNames":["Biological: onabotulinumtoxinA 44 U"]}],"interventions":[{"name":"normal saline","otherNames":[]},{"name":"onabotulinumtoxinA 44 U","otherNames":["BOTOX速","BOTOX速 Cosmetic","onabotulinumtoxinA"]},{"name":"onabotulinumtoxinA 24 U","otherNames":["BOTOX速","BOTOX速 Cosmetic","onabotulinumtoxinA"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Successfully completed Study 191622-099\n\nExclusion Criteria:\n\n* Known immunization or hypersensitivity to botulinum toxin of any serotype\n* Anticipated need for treatment with botulinum toxin of any serotype during the study (except for study treatment)\n* Diagnosis of myasthenia gravis, Eaton-Lambert syndrome, or amyotrophic lateral sclerosis\n* Anticipated need for surgery or hospitalization during the study","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants Achieving a Grade of None or Mild at Maximum Smile Based on the Investigator Facial Wrinkle Scale Assessment of the Severity of Crow's Feet Lines","description":"The investigator assessed the severity of the patient's Crow's Feet Lines at maximum smile using the 4-point Facial Wrinkle Scale: 0=none, 1=mild, 2=moderate or 3=severe. The percentage of participants with a score of none or mild at Day 30 is reported.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"63.6","spread":null},{"groupId":"OG001","value":"56.5","spread":null},{"groupId":"OG002","value":"1.1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":6,"n":349},"commonTop":["Injection site haematoma","Headache","Nasopharyngitis"]}}}